Patient description: Fernandez is a 41 year man who is a professional soccer player. He came to the clinic with itchy foot. Physical exam revealed localized scaling and maceration between the third and fourth of his right toe. It became inflamed and sore, with mild fissuring. The dorsum and sole of the foot was unaffected. There is no pus or tearing in the affected area. He didn't use ant topical ointment on the lesion and has no positive history for any underlying disease such as DM. He smokes 15 cigarettes per day and drinks a beer per day. His family history is positive for hyperlipidemia in her mother and MI in her father. He is in relation with several partners and use condom during the intercourse. His physical exam and lab studies were normal otherwise. Tinea pedis infection confirmed as his diagnosis by the observation of segmented fungal hyphae during a microscopic KOH wet mount examination.

Clinical trial eligibility criteria: eligible ages (years): 12.0-75.0,  Distal Subungual Onychomycosis Males or females 12 years of age 2. Distal subungual onychomycosis (DSO) of at least one of the great toenail(s) affecting 20% to 60% of the target nail 3. Positive culture for dermatophytes 4. Written informed consent  Proximal subungual onychomycosis 2. Distal subungual onychomycosis of both great toenails where involvement has extended into the proximal portion of the target nail (unaffected proximal nail is less than 3 mm) 3. Target toenail thickness more than 3 mm 4. "Spike" of onychomycosis extending to eponychium of the target toenail 5. Presence of dermatophytoma (defined as thick masses of fungal hyphae and necrotic keratin between the nail plate and nail bed) on the target nail 6. Other conditions than DSO known to cause abnormal nail appearance 7. Presence of toenail infection other than dermatophytes 8. Previous target toenail surgery with any residual disfigurement 9. Topical treatment of the nails with other antifungal medication within 6 weeks before screening/Visit 1 10. Systemic use of antifungal treatment within 6 months before screening/visit 1 11. Severe moccasin tinea pedis 12. Signs of severe peripheral circulatory insufficiency 13. Uncontrolled diabetes mellitus 14. Known immunodeficiency 15. Participation in another clinical trial with an investigational drug or device during the previous 3 months before Baseline/ Visit 2 16. Known allergy to any of the tested treatment products 17. A positive pregnancy test at Baseline/Visit 2 indicating pregnancy in a woman of childbearing potential or a premenarche subject 18. Females who are pregnant or breastfeeding 19. Men who have female sexual partners of child-bearing potential and sexually active women of child-bearing potential who are not practicing an acceptable method of birth control, or who will not remain abstinent through the trial. 20. Patients previously randomized in this study 21. History of, or current drug or alcohol abuse 22. Psychiatric condition that might limit the participation in the study and/or that lead to the assumption that the patient's ability to completely understand the consequences of consent is missing 23. Close affiliation with the investigator (e.g. a close relative) or persons working at a study site, or patient who is an employee of the sponsor's company 24. Patients who are institutionalized because of legal or regulatory order 25. Any diseases or circumstances in which the patient should not participate in the study in the opinion of the investigator